Ebola virus disease was first reported in Central Africa in 1976; it has the potential to cause massive bleeding. The mortality rate is about 50%. The virus is transmitted by contact with contaminated body fluids, including blood and semen.
Finally, antibodies against three of the major Ebola viruses were developed. Researchers at Vanderbilt University Medical Center have come one step closer to developing a highly effective antibody treatment against these viruses that cause deadly diseases in humans.
The researchers found that the isolation of two potent monoclonal antibodies from human survivors of Ebola virus disease in cell culture studies effectively neutralized the Ebola virus in Zaire, Sudan and Bundibugyo.
The antibodies, EBOV-515 and EBOV-520, have also demonstrated the ability to protect against infection by these viruses in animal models. The researchers said further studies are needed as these antibodies could lead to the development of injectable antibody “cocktails” for people at high risk of becoming infected with the Ebola virus.
The hope is that antibodies work like heat-seeking rockets that detect and destroy viruses before they can devastate the body.
Our team was delighted to discover these new antibodies that are able to treat all Ebola viruses, “said lead researcher James Crowe Jr. They appear to be very promising for development as a treatment and prevention of Ebola virus infections. Illness, “he added.
Ebola virus disease was first reported in Central Africa in 1976; It has the potential to cause massive bleeding. The mortality rate is about 50%. The virus is transmitted by contact with contaminated body fluids, including blood and semen.
A major epidemic in West Africa killed more than 11,000 people between 2014 and 2016. Earlier this month, the World Health Organization announced 29 deaths from a minor epidemic that began in April in the Democratic Republic of Congo. The study appears in the journal “Immunity.”